Relating to biomarker testing coverage.
HB 3421 requires specified health insurance policies, health care service contracts, and Oregon Health Plan medical assistance managed care arrangements to cover biomarker testing when the testing is prescribed for the diagnosis, treatment, management, or ongoing monitoring of a disease or condition and is supported by recognized sources of medical evidence. The bill defines key terms such as biomarker, biomarker testing, clinical practice guidelines, consensus statements, and prior authorization, and it ties required coverage to FDA labeling, FDA-approved or cleared drugs, CMS coverage determinations, and nationally recognized clinical guidelines or consensus statements.
The measure also requires that coverage be provided in a way that minimizes disruptions in care, including avoiding the need for multiple biopsies or repeated biospecimen collection when possible. It applies to policies and contracts issued, renewed, or extended on or after the effective date, and it amends Oregon statutes governing insurers, health care service contractors, coordinated care organizations, and the Oregon Health Authority to incorporate the new coverage mandate.
HB 3421 would expand Oregon insurance and Medicaid-related coverage rules by adding biomarker testing to the list of required benefits for many private health plans and for OHP managed care arrangements. It amends ORS 414.761, 750.055, and 750.333 to make the new coverage requirement applicable to coordinated care organizations, health care service contractors, and multiple employer welfare arrangements, and it treats these entities as insurers for purposes of the coverage mandate. The bill would affect insurers, health care providers ordering tests, and patients who may need molecular, genetic, or other biomarker-based testing for treatment decisions.
No committee transcripts or recorded votes were provided, so there is no documented floor or committee sentiment in the materials supplied. Based on the bill text alone, the measure appears to be framed as a patient-access and coverage expansion bill, with a technical implementation approach that relies on existing medical and federal coverage standards. The absence of recorded opposition or amendment history in the provided context means overall sentiment cannot be measured directly from legislative debate.
The main potential points of contention are likely to be cost, utilization management, and the scope of required coverage. Insurers may be concerned about expanded laboratory benefit obligations, the breadth of the evidence sources that can trigger coverage, and limits on prior authorization or utilization review practices. Supporters would likely emphasize improved access to precision medicine and reduced delays in diagnosis and treatment, while any opposition would probably focus on premium impacts, administrative burden, and whether the bill mandates coverage for tests that some plans might otherwise deny or restrict.